Medical device company TransEnterix Inc (NYSE MKT:TRXC) stated on Monday that it recorded a net loss of USD120.0m (USD1.07 per share) for the full year ended 31 December 2016.
This reflects a decrease in earnings when compared with net loss of USD46.9m (USD0.59 per share) for the full year ended 31 December 2015.
Revenues of USD1.5m were generated for the full year ended 31 December 2016, over nil for the full year ended 31 December 2015.
The company said the 2016 revenues represent the sale of a Senhance system, net of deferred revenue, as well as the recognition of deferred and service revenue associated with existing placements.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government